EndoVascular Instruments Inc.
Less Invasive,
longer lasting treatment for
Peripheral Arterial Disease
EndoVascular Instruments Kit Advantages
-
Comparable patency to conventional bypass but at lower cost, less patient discomfort and shorter hospital stays
-
Superior patency to endovascular techniques
-
Can be used for first time procedures and revision of failed endovascular procedures. Occluded stents can now be removed, significantly increasing the utility of this method.
EVI Products
Ready For Manufacturing
Patents
US Patent No.: 11,534,198 B2 was issued on December 27, 2022 for more effectively removing plaque and failed stents from arteries.
Five additional US patent applications are currently pending including:
-
A 3-Step Patent that builds on earlier 2-step patented method
-
Stent/Graft Design: An ePTFE graft with an ePTFE-covered distal stent.
NEWS
WHY
CASPER, WYOMING?
The Team
Tom Wiita, MBA
President& CEO
Thomas A. Wiita, Chairman, President and CEO. Mr. Wiita is a serial entrepreneur with multiple successes in the medical device field, including Catheter Technology (the Groshong catheters acquired by CR Bard earning $6 to $1 returns for investors), Iomed, Inc. (ASE symbol IOX, later acquired by ReAble/Empi) and Catheter Innovations (PASV catheters acquired by Boston Scientific earning $3 to $1 returns on a short, two-year holding period).
Tom Kelly, PE
R & D Engineering Consultant
Mr. Kelly is an Engineering Consultant and assisted in the design, manufacturing and marketing for EVI. Kelly has served as a senior engineer and manager for companies involved in the design, manufacture and marketing of proprietary products for the health care industry.
Robert Delahunty, JD
Legal Counsel
Bob Delahunty is a shareholder of Parsons Behle & Latimer and is a member of the firm’s Corporate and Tax department. He advises and assists clients on business matters involving corporate, securities and general commercial law, with an emphasis on structuring, negotiating, and documenting complex transactions. He has advised companies that utilize emerging technology in a broad range of matters, including the purchase, sale and financing of businesses, mergers, proxy statements and SEC compliance work and complex licensing arrangements.
Mr. Delahunty began practice as an associate with Sheppard, Mullin, Richter & Hampton in Los Angeles,California; became an associate and shareholder at the Salt Lake City law firm of Prince, Yeates & Geldzahler; and from 1982 until he joined Parsons in May of 1992, was a founding partner/shareholder of Hansen Jones & Leta.
Nick Raible, MS
Sales and Marketing Consultant
Having worked for both WL Gore and Impra, Nick has expertise with ePTFE grafts and hemodynamics. He has managed sales teams in the vascular market and provides strategic and tactical support to EndoVascular Instruments.
John DeFeo
Business Development Consultant
John is a serial CEO & Venture Capitalist with extensive experience solving business problems and scaling start ups for growth.
Contact
Tom Wiita
President & CEO
307-797-7588